Zevra Therapeutics (ZVRA) Interest & Investment Income (2014 - 2026)
Zevra Therapeutics (ZVRA) reported Interest & Investment Income of $3.6 million for Q1 2026, up 560.96% on a YoY basis from $543000.0 in Q1 2025, and up 109.64% quarter-over-quarter from $1.7 million in Q4 2025.
Zevra Therapeutics (ZVRA) Interest & Investment Income (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported Interest & Investment Income for 13 years, with the latest figure at $3.6 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 560.96% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $10.0 million (up 458.52% YoY), and the FY2025 full-year result was $6.9 million, up 219.36% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $3.6 million, up from $1.7 million in the prior quarter.
- The five-year high for Interest & Investment Income was $3.6 million in Q1 2026, with the low at -$73000.0 in Q4 2024.
- Historically, Interest & Investment Income has averaged $1.1 million across 5 years, with a median of $1.0 million in 2023.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 12533.33% — and 2024, when it slumped 134.76%.
- Zevra Therapeutics' Interest & Investment Income stood at $278000.0 in 2022, then declined by 24.46% to $210000.0 in 2023, then tumbled by 134.76% to -$73000.0 in 2024, then jumped by 2445.21% to $1.7 million in 2025, then jumped by 109.64% to $3.6 million in 2026.
- The last three Interest & Investment Income figures came in at $3.6 million (Q1 2026), $1.7 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -14.79 Mn |
| 10 | Zevra Therapeutics | 787.90 Mn | 587.28 Mn | 34.30 Mn | 3.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.59 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.38 Mn |
| Mar 31, 2025 | 543,000.00 |
| Dec 31, 2024 | -73,000.00 |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 270,000.00 |
| Mar 31, 2024 | 929,000.00 |
| Dec 31, 2023 | 210,000.00 |
| Sep 30, 2023 | 1.74 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | 278,000.00 |
| Sep 30, 2022 | 218,000.00 |
| Jun 30, 2022 | 1.12 Mn |
| Mar 31, 2022 | 107,000.00 |
| Dec 31, 2021 | 125,000.00 |
| Sep 30, 2021 | 137,000.00 |
| Jun 30, 2021 | -9,000.00 |